StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $2.31 | $2.41 | +4.33% | 6.3M |
| 05-13 | $2.41 | $2.44 | +1.24% | 3.3M |
| 05-14 | $2.44 | $2.33 | -4.51% | 2.5M |
| 05-15 | $2.29 | $2.23 | -2.41% | 2.1M |
| 05-18 | $2.22 | $2.14 | -3.60% | 2.2M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
| Metric | Q1 2025 2025-03-31 | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 | Q2 2024 2024-06-30 |
|---|---|---|---|---|
Revenue | $1.26M | $6.00M | $4.45M | $2.71M |
Operating Income | $-25.68M | $-197.12M | $-164.38M | $-100.69M |
Net Income | $-25.30M | $-200.40M | $-166.64M | $-53.43M |
EPS (Diluted) | $-0.07 | $-0.63 | $-0.54 | $-0.37 |
Total Assets | $297.67M | $298.42M | $321.12M | $373.36M |
Total Liabilities | $174.64M | $152.47M | $142.61M | $133.38M |
Cash & Equivalents | $62.89M | $66.66M | $34.55M | $35.62M |
Free Cash Flow OCF − CapEx | Not available | $-179.81M | $-157.85M | $-103.92M |
Shares Outstanding | 362.07M | 363.02M | 306.11M | 278.11M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.